3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Classical hematology
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Pulmonary Embolism
1
Gastrointestinal Neoplasms
1
Interventions
Cyclophosphamide
11
fludarabine phosphate
9
Whole-Body Irradiation
8
Mycophenolic Acid
7
Busulfan
6
fludarabine
5
Tacrolimus
5
Peripheral Blood Stem Cell Transplantation
5
Melphalan
5
Rituximab
4
Biopsy
4
Azacitidine
4
venetoclax
3
apixaban
3
Cyclosporine
3
thymoglobulin
2
decitabine and cedazuridine drug combination
2
Vorinostat
2
Vancomycin
2
Tretinoin
2
Specimen Handling
2
Sirolimus
2
Methotrexate
2
Lenalidomide
2
Injections
2
Granulocyte Colony-Stimulating Factor
2
Filgrastim
2
Etoposide
2
Decitabine
2
Cytarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Dalteparin
×
Classical hematology
×
90 days
×
Clear all
NCT05171075
2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3
Terminated
417 enrolled